CA2920534A1 - Methods for the treatment of her2 amplified cancer - Google Patents

Methods for the treatment of her2 amplified cancer Download PDF

Info

Publication number
CA2920534A1
CA2920534A1 CA2920534A CA2920534A CA2920534A1 CA 2920534 A1 CA2920534 A1 CA 2920534A1 CA 2920534 A CA2920534 A CA 2920534A CA 2920534 A CA2920534 A CA 2920534A CA 2920534 A1 CA2920534 A1 CA 2920534A1
Authority
CA
Canada
Prior art keywords
her2
ibrutinib
therapeutic agent
cancer
amplified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2920534A
Other languages
English (en)
French (fr)
Inventor
Jun Chen
Joseph J. Buggy
Laurence Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52448841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2920534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CA2920534A1 publication Critical patent/CA2920534A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2920534A 2013-08-12 2014-08-12 Methods for the treatment of her2 amplified cancer Abandoned CA2920534A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865059P 2013-08-12 2013-08-12
US61/865,059 2013-08-12
US201461969003P 2014-03-21 2014-03-21
US61/969,003 2014-03-21
PCT/US2014/050783 WO2015023703A1 (en) 2013-08-12 2014-08-12 Methods for the treatment of her2 amplified cancer

Publications (1)

Publication Number Publication Date
CA2920534A1 true CA2920534A1 (en) 2015-02-19

Family

ID=52448841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920534A Abandoned CA2920534A1 (en) 2013-08-12 2014-08-12 Methods for the treatment of her2 amplified cancer

Country Status (6)

Country Link
US (5) US9415050B2 (enExample)
EP (1) EP3033079B1 (enExample)
JP (3) JP6429292B2 (enExample)
CA (1) CA2920534A1 (enExample)
ES (1) ES2709509T3 (enExample)
WO (1) WO2015023703A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2015023703A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
US20160206646A1 (en) * 2013-08-20 2016-07-21 The Research Foundation For The State University Of New York Bruton's Tyrosine Kinase as Anti-Cancer Drug Target
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
WO2016141044A1 (en) * 2015-03-04 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Erbb4 inhibitors and methods of use thereof
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
DK3892302T3 (da) * 2015-04-06 2023-11-13 Janssen Pharmaceutica Nv Sammensætninger indeholdende ibrutinib
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
MA42546A (fr) * 2015-07-31 2018-06-06 Pharmacyclics Llc Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
DK3345907T3 (da) * 2015-09-01 2020-06-22 Taiho Pharmaceutical Co Ltd Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
US10668068B2 (en) * 2015-10-07 2020-06-02 The Research Foundation For The State University Of New York Treating cancer with drug combinations
CN107349426B (zh) * 2017-07-12 2018-03-23 马骥 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
TWI798334B (zh) 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
WO2022056592A1 (en) * 2020-09-16 2022-03-24 Olivia Newton-John Cancer Research Institute Treatment and/or prevention of cancers
JP2024505342A (ja) * 2020-12-23 2024-02-06 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド メタクリルアミド系タンパク質結合剤及びその使用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
MXPA00010150A (es) 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
NZ517758A (en) 1999-09-17 2004-06-25 Abbott Gmbh & Co Pyrazolopyrimidines useful as therapeutic agents
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP5036112B2 (ja) 1999-10-06 2012-09-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有益な複素環化合物
EP1235567A2 (en) 1999-11-30 2002-09-04 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
WO2001044258A1 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
HUP0303656A3 (en) 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
WO2002045684A2 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
IL161409A0 (en) 2001-11-21 2004-09-27 Sunesis Pharmaceuticals Inc Methods for ligand discovery
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
JP2007519742A (ja) 2004-01-26 2007-07-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼの阻害剤として有用な組成物
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP2008513032A (ja) 2004-09-22 2008-05-01 トリパス イメージング， インコーポレイテッド 乳癌の予後を評価するための方法および組成物
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
WO2006036527A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine ccr2 antagonists
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
ATE492545T1 (de) 2005-05-13 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
US7625880B2 (en) 2006-01-13 2009-12-01 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
US20090317836A1 (en) 2006-01-30 2009-12-24 The Scripps Research Institute Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CN102671196B (zh) 2006-04-05 2014-12-03 诺华股份有限公司 用于治疗癌症的治疗剂的组合
JP5682051B2 (ja) 2006-05-18 2015-03-11 ファーマサイクリックス，インク． 細胞内キナーゼ阻害剤
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
US8660039B2 (en) 2007-01-08 2014-02-25 Intracom Systems, Llc Multi-channel multi-access voice over IP intercommunication systems and methods
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
NZ579911A (en) 2007-03-28 2012-05-25 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2679436C (en) 2007-04-05 2018-10-23 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US8532276B2 (en) 2007-06-26 2013-09-10 Ingenio Llc Systems and methods to provide telephonic connections via concurrent calls
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2920996A1 (en) 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5587193B2 (ja) 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
NZ589843A (en) 2008-06-27 2012-12-21 Avila Therapeutics Inc Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
US20110224235A1 (en) 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8633311B2 (en) 2008-07-29 2014-01-21 Frontier Scientific, Inc. Topical application of porphyrins for killing or preventing the growth of bacteria or fungi on a mammal
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
MX2012006994A (es) 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
RU2598852C2 (ru) 2010-06-23 2016-09-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
ES2617763T3 (es) 2010-08-10 2017-06-19 Celgene Avilomics Research, Inc. Sal de besilato de un inhibidor de BTK
US20120202611A1 (en) 2011-02-07 2012-08-09 Terry Warren Sports training device
ES2590778T3 (es) * 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
US8722080B2 (en) 2011-03-11 2014-05-13 Gary D. Hack Treatment and prevention of dental pathology in humans and non-human animals
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US20130016060A1 (en) 2011-07-12 2013-01-17 Research In Motion Limited Electronic device and method of controlling a touch-sensitive display
US8476264B2 (en) 2011-09-21 2013-07-02 Hoffmann-La Roche Inc. N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors
KR20230109775A (ko) 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
WO2014078578A1 (en) 2012-11-15 2014-05-22 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
CN105263496A (zh) 2013-04-08 2016-01-20 药品循环有限责任公司 依鲁替尼联合疗法
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
WO2015023703A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
AU2014339816B2 (en) 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
CA2929181A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy

Also Published As

Publication number Publication date
JP6429292B2 (ja) 2018-11-28
US9415050B2 (en) 2016-08-16
EP3033079B1 (en) 2018-10-31
US9724349B2 (en) 2017-08-08
US20150044217A1 (en) 2015-02-12
EP3033079A1 (en) 2016-06-22
EP3033079A4 (en) 2017-04-05
JP2021008475A (ja) 2021-01-28
ES2709509T3 (es) 2019-04-16
US20180071294A1 (en) 2018-03-15
US20190167687A1 (en) 2019-06-06
US20210145835A1 (en) 2021-05-20
WO2015023703A1 (en) 2015-02-19
US10016434B2 (en) 2018-07-10
US20170151243A1 (en) 2017-06-01
JP2016528251A (ja) 2016-09-15
JP2019031546A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
US10016434B2 (en) Methods for the treatment of HER2 amplified cancer
US20240065971A1 (en) Methods of treating abc-dlbcl using inhibitors of brutons tyrosine kinase
JP7042950B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
US20160022684A1 (en) Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
AU2015350136A1 (en) TLR inhibitor and Bruton's tyrosine kinase inhibitor combinations
JP2012509859A (ja) 中皮腫の治療のためのｃｄｋ阻害物質
MX2014004647A (es) Uso de inhibidores de la tirosina cinasa de bruton (btk).
WO2015084892A1 (en) Methods for treating b cell proliferative disorders
US20150352116A1 (en) Hdac inhibitor and btk inhibitor combinations
WO2017011314A1 (en) Btk and hdac combinations
US20230321094A1 (en) Combination therapies with olig2 inhibitors
HK1185279A (en) The use of inhibitors of bruton's tyrosine kinase (btk)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190809

FZDE Discontinued

Effective date: 20220321

FZDE Discontinued

Effective date: 20220321